Drug Trial Radar · NCT01931839
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
Last checked: Nov 19, 2026Latest source record: May 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,164
Actual
Start
Oct 2013
Primary completion
Apr 2016
Study completion Apr 2016
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Aug 29, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of long-term treatment with lumacaftor in combination with ivacaftor in people 12 years and older with Cystic Fibrosis.
Conditions
- Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Interventions
Lumacaftor Plus Ivacaftor CombinationDrug
Fixed dose combination tablet, oral use
IvacaftorDrug
Film-coated tablet, oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A Treatment Cohort: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 105 (Study 105)
- Part B Treatment Cohort: Number of Participants With Treatment-Emergent AEs and SAEsTime frame: Day 1 up to Week 105 (Study 105)
Locations
166 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Anchorage, Alaska
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
La Jolla, California
Site not named
Loma Linda, California
Site not named
Longbeach, California
Site not named
Los Angeles, California
Site not named
Madera, California
Site not named
Oakland, California
Site not named
Palo Alto, California
Site not named
Sacramento, California
Site not named
Aurora, Colorado
Site not named
Denver, Colorado
Site not named
Hartford, Connecticut
Site not named
New Haven, Connecticut
Site not named
Altamonte Springs, Florida
Site not named
Hollywood, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Boise, Idaho
Site not named
Chicago, Illinois
Site not named
Park Ridge, Illinois
Site not named
Peoria, Illinois
Site not named
Indianapolis, Indiana
Site not named
Iowa City, Iowa
Site not named
Kansas City, Kansas
Site not named
Lexington, Kentucky
Site not named
New Orleans, Louisiana
Site not named
South Portland, Maine
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Worcester, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Detroit, Michigan
Site not named
Grand Rapids, Michigan
Site not named
Minneapolis, Minnesota
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.